Slightly tangential to FAERS pharmacovigilance but MASHdoc_SA reminded me — what is the latest on the oral formulations?
I know it is not exactly on-topic but it seems related enough to ask here rather than starting a new thread. Apologies if this has been covered — I did search first.
Thanks for sharing this, MASHdoc_SA. A few questions about your FAERS pharmacovigila experience:
- What dose worked best for you?
- How long before you noticed appetite suppression kicking in?
- Did your endo have any specific recommendations about FAERS pharmacov?
I am in a similar boat and trying to learn from others' experiences before my next appointment.
PeptideMeter — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsOP here — wow, did not expect this much response! Thank you all for the thoughtful replies on FAERS pharmacovigilance.
To answer LeilaHI: yes, I am on compounded sema from a 503B pharmacy.
Quick update: things are still going well. Thanks again for the evidence-based discussion — this is exactly why I posted in a science-based community. 🙏
Relevant to FAERS pharmacovigilance data — here is my latest bloodwork comparison:
Key improvements: A1C 7.6% → 5.5%, triglycerides 197 → 97 mg/dL, hsCRP 8.0 → 0.9 mg/L. All on tirzepatide for 13 months.
The inflammatory marker drop is what impresses me most. Consistent with the SELECT trial's cardiovascular findings.